Mark Faries, MD, surgical oncologist, Cedars?Sinai, The Angeles Clinic and Research Institute; associate director, Surgical Oncology Experimental Therapeutics, Cedars Sinai Department of Surgery; and head, surgical oncology, Cedars-Sinai Medical Center, discusses how CAR T-cell therapies and transgenic T-cell receptor (TCR) cell therapies compare with current tumor-infiltrating lymphocyte (TIL) approaches in melanoma.
Of Interest
Vitamin E succinate controls tumor growth and enhances immunotherapy effects
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to immunotherapy. In a study recently published in PNAS, researchers from the University of Chicago Medicine identified vitamin E succinate (VES) as an effective agent in controlling tumor growth by promoting the degradation of FTO.
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Teresa Petrella, MD, MHSc, FRCPC, medical oncologist, affiliate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute; and associate professor, Department of Medicine, University of Toronto, discusses key considerations in selecting frontline therapy for patients with metastatic melanoma based on long-term survival data and therapeutic sequencing findings.
Trauma-Induced Melanocyte Implantation Leading to Subcutaneous Melanoma
Trauma-induced melanocyte implantation can lead to subcutaneous melanoma, mimicking melanoma of unknown primary but with distinct diagnostic criteria.